|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: GNB2L1 |
Gene summary for GNB2L1 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | GNB2L1 | Gene ID | 10399 |
| Gene name | receptor for activated C kinase 1 | |
| Gene Alias | GNB2L1 | |
| Cytomap | 5q35.3 | |
| Gene Type | protein-coding | GO ID | GO:0000302 | UniProtAcc | E9KL35 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 10399 | GNB2L1 | GSM4909277 | Human | Breast | Precancer | 4.91e-03 | -1.11e+00 | 0.0177 |
| 10399 | GNB2L1 | GSM4909280 | Human | Breast | Precancer | 1.33e-06 | -1.11e+00 | 0.0305 |
| 10399 | GNB2L1 | GSM4909281 | Human | Breast | IDC | 6.38e-36 | -1.11e+00 | 0.21 |
| 10399 | GNB2L1 | GSM4909282 | Human | Breast | IDC | 6.38e-36 | -1.11e+00 | -0.0288 |
| 10399 | GNB2L1 | GSM4909285 | Human | Breast | IDC | 6.38e-36 | -1.11e+00 | 0.21 |
| 10399 | GNB2L1 | GSM4909286 | Human | Breast | IDC | 1.65e-35 | -1.11e+00 | 0.1081 |
| 10399 | GNB2L1 | GSM4909287 | Human | Breast | IDC | 3.68e-41 | -1.11e+00 | 0.2057 |
| 10399 | GNB2L1 | GSM4909288 | Human | Breast | IDC | 5.57e-12 | -1.11e+00 | 0.0988 |
| 10399 | GNB2L1 | GSM4909289 | Human | Breast | IDC | 3.61e-09 | -1.11e+00 | 0.1064 |
| 10399 | GNB2L1 | GSM4909290 | Human | Breast | IDC | 1.74e-30 | -1.11e+00 | 0.2096 |
| 10399 | GNB2L1 | GSM4909291 | Human | Breast | IDC | 2.52e-25 | -1.11e+00 | 0.1753 |
| 10399 | GNB2L1 | GSM4909292 | Human | Breast | IDC | 3.65e-05 | -1.11e+00 | 0.1236 |
| 10399 | GNB2L1 | GSM4909293 | Human | Breast | IDC | 6.38e-36 | -1.11e+00 | 0.1581 |
| 10399 | GNB2L1 | GSM4909294 | Human | Breast | IDC | 6.38e-36 | -1.11e+00 | 0.2022 |
| 10399 | GNB2L1 | GSM4909295 | Human | Breast | IDC | 1.46e-20 | -1.11e+00 | 0.0898 |
| 10399 | GNB2L1 | GSM4909296 | Human | Breast | IDC | 2.45e-36 | -1.11e+00 | 0.1524 |
| 10399 | GNB2L1 | GSM4909297 | Human | Breast | IDC | 1.37e-37 | -1.11e+00 | 0.1517 |
| 10399 | GNB2L1 | GSM4909298 | Human | Breast | IDC | 1.65e-35 | -1.11e+00 | 0.1551 |
| 10399 | GNB2L1 | GSM4909299 | Human | Breast | IDC | 1.65e-35 | -1.11e+00 | 0.035 |
| 10399 | GNB2L1 | GSM4909300 | Human | Breast | IDC | 1.68e-18 | -1.11e+00 | 0.0334 |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| GC |  | CAG: Chronic atrophic gastritis |
| CAG with IM: Chronic atrophic gastritis with intestinal metaplasia | ||
| CSG: Chronic superficial gastritis | ||
| GC: Gastric cancer | ||
| SIM: Severe intestinal metaplasia | ||
| WIM: Wild intestinal metaplasia | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa051629 | Esophagus | ESCC | Measles | 90/4205 | 139/8465 | 2.16e-04 | 7.87e-04 | 4.03e-04 | 90 |
| hsa0516213 | Esophagus | ESCC | Measles | 90/4205 | 139/8465 | 2.16e-04 | 7.87e-04 | 4.03e-04 | 90 |
| hsa05162 | Lung | IAC | Measles | 27/1053 | 139/8465 | 1.16e-02 | 4.20e-02 | 2.79e-02 | 27 |
| hsa051621 | Lung | IAC | Measles | 27/1053 | 139/8465 | 1.16e-02 | 4.20e-02 | 2.79e-02 | 27 |
| hsa051628 | Oral cavity | OSCC | Measles | 90/3704 | 139/8465 | 4.10e-07 | 2.50e-06 | 1.27e-06 | 90 |
| hsa0516212 | Oral cavity | OSCC | Measles | 90/3704 | 139/8465 | 4.10e-07 | 2.50e-06 | 1.27e-06 | 90 |
| hsa0516241 | Oral cavity | EOLP | Measles | 42/1218 | 139/8465 | 1.11e-06 | 9.96e-06 | 5.87e-06 | 42 |
| hsa051625 | Oral cavity | EOLP | Measles | 42/1218 | 139/8465 | 1.11e-06 | 9.96e-06 | 5.87e-06 | 42 |
| hsa051626 | Oral cavity | NEOLP | Measles | 35/1112 | 139/8465 | 8.30e-05 | 6.14e-04 | 3.86e-04 | 35 |
| hsa051627 | Oral cavity | NEOLP | Measles | 35/1112 | 139/8465 | 8.30e-05 | 6.14e-04 | 3.86e-04 | 35 |
| hsa051624 | Prostate | BPH | Measles | 42/1718 | 139/8465 | 3.35e-03 | 1.23e-02 | 7.61e-03 | 42 |
| hsa0516211 | Prostate | BPH | Measles | 42/1718 | 139/8465 | 3.35e-03 | 1.23e-02 | 7.61e-03 | 42 |
| hsa051622 | Prostate | Tumor | Measles | 44/1791 | 139/8465 | 2.33e-03 | 8.85e-03 | 5.49e-03 | 44 |
| hsa051623 | Prostate | Tumor | Measles | 44/1791 | 139/8465 | 2.33e-03 | 8.85e-03 | 5.49e-03 | 44 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| Page: 1 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |